The CALOR (Chemotherapy as Adjuvant for Locally Recurrent) trial investigated chemotherapy in isolated locoregional breast cancer recurrence. Its primary finding was that chemotherapy benefit was confined to which subgroup?
- A ER-negative breast cancer recurrences ✓
- B HER2-positive breast cancer recurrences
- C Premenopausal women at recurrence
- D Recurrences within 2 years of primary treatment
Correct answer: A. ER-negative breast cancer recurrences
Explanation
The CALOR trial showed that adjuvant chemotherapy improved disease-free and overall survival following complete resection of isolated locoregional recurrence only in women with ER-negative tumours; no significant benefit was observed in ER-positive recurrences. This underscores the importance of tumour biology rather than timing or menopausal status in determining chemotherapy benefit at recurrence. HER2 status was not the defining stratification factor in CALOR.
Reference: Bailey & Love's Short Practice of Surgery, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.